Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Leukemia

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 187 articles:
HTML format
Text format



Single Articles


    January 2019
  1. KHAKWANI M, Srinath S, Pratt G, Moss P, et al
    A rare complication of bone marrow aspiration and trephine biopsy: Staphylococcus aureus osteomyelitis and septicaemia.
    Br J Haematol. 2019;184:7.
    PubMed     Text format    


  2. HU AY, Zhou T
    Sequential B-lymphoid and myeloid blastic transformation of Philadelphia chromosome-negative myeloproliferative neoplasm.
    Br J Haematol. 2019;184:8.
    PubMed     Text format    


    June 2018
  3. YEOH AE, Li Z, Dong D, Lu Y, et al
    Effective Response Metric: a novel tool to predict relapse in childhood acute lymphoblastic leukaemia using time-series gene expression profiling.
    Br J Haematol. 2018;181:653-663.
    PubMed     Text format     Abstract available


  4. MOZESSOHN L, Cheung MC, Fallahpour S, Gill T, et al
    Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
    Br J Haematol. 2018;181:803-815.
    PubMed     Text format     Abstract available


  5. ZHOU W, Goldin L, Wang M, McMaster ML, et al
    Combined somatic mutation and copy number analysis in the survival of familial CLL.
    Br J Haematol. 2018;181:604-613.
    PubMed     Text format     Abstract available


  6. CHIARETTI S, Messina M, Grammatico S, Piciocchi A, et al
    Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.
    Br J Haematol. 2018;181:642-652.
    PubMed     Text format     Abstract available


  7. BLAYNEY JK, Mills KI
    Compositional analysis gives insight into leukaemia cell lines expression profiles compared to those within patient sub-groups.
    Br J Haematol. 2018;181:847-851.
    PubMed     Text format    


  8. AW A, Hellman JM, Birner A, Davids MS, et al
    A complex case of ibrutinib treatment for a CLL patient on haemodialysis.
    Br J Haematol. 2018;181:854-857.
    PubMed     Text format    


  9. MCCLAIN CA, Bernhardt MB, Berger A, Bernini JC, et al
    Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
    Br J Haematol. 2018;181:684-687.
    PubMed     Text format    


  10. GHIONE P, Genuardi E, Rossi D, Drandi D, et al
    Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.
    Br J Haematol. 2018;181:693-695.
    PubMed     Text format    


  11. MEI H, Jiang H, Wu Y, Guo T, et al
    Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy.
    Br J Haematol. 2018;181:689-692.
    PubMed     Text format    


    May 2018
  12. SUTTON R
    Age matters in ALL.
    Br J Haematol. 2018;181:429-430.
    PubMed     Text format    


  13. SELLAR RS, Rowntree C, Vora AJ, Furness CL, et al
    Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003.
    Br J Haematol. 2018;181:515-522.
    PubMed     Text format     Abstract available


  14. SELLAR RS, Gale RE, Khwaja A, Garbowski M, et al
    Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome.
    Br J Haematol. 2018;181:486-494.
    PubMed     Text format     Abstract available


  15. KASPERS GJL, Niewerth D, Wilhelm BAJ, Scholte-van Houtem P, et al
    An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
    Br J Haematol. 2018;181:523-527.
    PubMed     Text format     Abstract available


  16. JIMENEZ JJ, DelCanto GM, Popovics P, Perez A, et al
    A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone.
    Br J Haematol. 2018;181:476-485.
    PubMed     Text format     Abstract available


  17. LI S, Zhang J, Wang M, Fu G, et al
    Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
    Br J Haematol. 2018;181:360-371.
    PubMed     Text format     Abstract available


  18. PORPACZY E, Skrabs C, Schwarzinger I, Augustin D, et al
    Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib.
    Br J Haematol. 2018;181:431.
    PubMed     Text format    


  19. KURT H, Khoury JD, Medeiros LJ, Huh YO, et al
    Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations.
    Br J Haematol. 2018;181:305.
    PubMed     Text format    


  20. LOHSE S, Loew S, Kretschmer A, Jansen JHM, et al
    Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
    Br J Haematol. 2018;181:413-417.
    PubMed     Text format    


  21. MARTINEZ-LAPERCHE C, Kwon M, Franco-Villegas AC, Chillon MC, et al
    Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology.
    Br J Haematol. 2018;181:542-546.
    PubMed     Text format    


    April 2018
  22. FRIDTHJOF KS, Kampmann P, Dunweber A, Gorlov JS, et al
    Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15249.
    PubMed     Text format     Abstract available


  23. RIGOLIN GM, Saccenti E, Guardalben E, Cavallari M, et al
    In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.
    Br J Haematol. 2018;181:229-233.
    PubMed     Text format     Abstract available


  24. OSTGARD LSG, Norgaard M, Pedersen L, Ostgard RD, et al
    Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.
    Br J Haematol. 2018;181:205-214.
    PubMed     Text format     Abstract available


  25. CRASSINI KR, Zhang E, Balendran S, Freeman JA, et al
    Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia.
    Br J Haematol. 2018;181:97-101.
    PubMed     Text format     Abstract available


  26. HOBO W, Hutten TJA, Schaap NPM, Dolstra H, et al
    Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.
    Br J Haematol. 2018;181:38-53.
    PubMed     Text format     Abstract available


  27. RASHIDI A, Weisdorf DJ, Bejanyan N
    Treatment of relapsed/refractory acute myeloid leukaemia in adults.
    Br J Haematol. 2018;181:27-37.
    PubMed     Text format     Abstract available


  28. SHRUBSOLE C, Collin M
    Tumour genesis syndrome in relapsed B lymphoblastic leukaemia.
    Br J Haematol. 2018;181:160.
    PubMed     Text format    


  29. DEMYANETS S, Jaeger E, Pablik E, Greiner G, et al
    The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia.
    Br J Haematol. 2018;181:137-139.
    PubMed     Text format    


  30. MATO AR, Timlin C, Ujjani C, Skarbnik A, et al
    Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
    Br J Haematol. 2018;181:259-261.
    PubMed     Text format    


  31. LIAO K, Zheng Z, Yang L, Wang L, et al
    Analysis of high-resolution human leucocyte antigen allele polymorphism in 3788 Han Chinese patients with leukaemia.
    Br J Haematol. 2018;181:278-281.
    PubMed     Text format    


  32. ARAI H, Nobusawa S, Kawabata-Iwakawa R, Rokudai S, et al
    Myeloid sarcoma arising in malignant phyllodes tumour: clonal relationships revealed by comparative genome-wide analyses.
    Br J Haematol. 2018;181:255-259.
    PubMed     Text format    


  33. MOLICA M, Breccia M, Colafigli G, Massaro F, et al
    Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
    Br J Haematol. 2018;181:275-278.
    PubMed     Text format    


  34. SORA F, Iurlo A, Sica S, Latagliata R, et al
    Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome.
    Br J Haematol. 2018;181:267-270.
    PubMed     Text format    


  35. SOLER AM, Olano N, Mendez Y, Lopes A, et al
    TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay.
    Br J Haematol. 2018;181:252-255.
    PubMed     Text format    


  36. SCHULZ E, Lind K, Renner W, Petersen BS, et al
    The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls.
    Br J Haematol. 2018;181:148-151.
    PubMed     Text format    


    March 2018
  37. LOVISA F, Zecca M, Rossi B, Campeggio M, et al
    Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2018;180:680-693.
    PubMed     Text format     Abstract available


  38. GRIBBEN JG, Bosch F, Cymbalista F, Geisler CH, et al
    Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
    Br J Haematol. 2018;180:666-679.
    PubMed     Text format     Abstract available


  39. OHANIAN M, Pemmaraju N, Rozovski U, Alattar ML, et al
    Ocular extramedullary myeloid leukaemia.
    Br J Haematol. 2018;180:738-740.
    PubMed     Text format    


  40. STECKEL NK, Groth C, Mikesch JH, Trenschel R, et al
    High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2018;180:840-853.
    PubMed     Text format     Abstract available


  41. GUTIERREZ A, Kentsis A
    Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy.
    Br J Haematol. 2018;180:919-924.
    PubMed     Text format     Abstract available


  42. KONG Y, Song Y, Tang FF, Zhao HY, et al
    N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant.
    Br J Haematol. 2018;180:863-878.
    PubMed     Text format     Abstract available


  43. JURCZYSZYN A, Radocha J, Davila J, Fiala MA, et al
    Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
    Br J Haematol. 2018;180:831-839.
    PubMed     Text format     Abstract available


  44. GUZELKUCUK Z, Isik M, Ozcan AS, Demirkan TH, et al
    Imatinib-related interstitial lung disease.
    Br J Haematol. 2018;180:780.
    PubMed     Text format    


  45. DUTTA A, Yan D, Hutchison RE, Mohi G, et al
    STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice.
    Br J Haematol. 2018;180:911-915.
    PubMed     Text format    


  46. LANGE AP, Lima AS, Lucena-Araujo AR, Jacomo RH, et al
    The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia.
    Br J Haematol. 2018;180:915-918.
    PubMed     Text format    


  47. GIONA F, Saglio G, Santopietro M, Menna G, et al
    Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib.
    Br J Haematol. 2018;180:895-898.
    PubMed     Text format    


    February 2018
  48. STOLZEL F
    From remission to cure: bypass or detour?
    Br J Haematol. 2018;180:317-318.
    PubMed     Text format    


  49. SUTTON R, Venn NC, Law T, Boer JM, et al
    A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
    Br J Haematol. 2018;180:550-562.
    PubMed     Text format     Abstract available


  50. KAYSER S, Levis MJ
    Advances in targeted therapy for acute myeloid leukaemia.
    Br J Haematol. 2018;180:484-500.
    PubMed     Text format     Abstract available


  51. HSU YT, Chen TY
    Relapsing polychondritis as a presenting feature of acute myeloid leukaemia.
    Br J Haematol. 2018;180:472.
    PubMed     Text format    


  52. ROUTLEDGE DJM, Tower C, Davies E, Scott M, et al
    Successful management of acute myeloid leukaemia in a twin pregnancy - a case report.
    Br J Haematol. 2018;180:605-606.
    PubMed     Text format    


  53. SIVINA M, Werner L, Rassenti L, Ferrajoli A, et al
    Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.
    Br J Haematol. 2018;180:597-600.
    PubMed     Text format    


  54. MAHDI AJ, Gosrani D, Chakraborty M, Rees A, et al
    Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
    Br J Haematol. 2018;180:603-604.
    PubMed     Text format    


  55. CONY-MAKHOUL P, Gardembas M, Coiteux V, Carpentier N, et al
    Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.
    Br J Haematol. 2018;180:356-364.
    PubMed     Text format     Abstract available


  56. DAVIES JK, Hassan S, Sarker SJ, Besley C, et al
    Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
    Br J Haematol. 2018;180:346-355.
    PubMed     Text format     Abstract available


  57. TANG FF, Xu LP, Zhang XH, Chen H, et al
    Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.
    Br J Haematol. 2018;180:448-451.
    PubMed     Text format    


    January 2018
  58. GOCKE CD, Gladstone DE
    The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
    Br J Haematol. 2018;180:7-8.
    PubMed     Text format    


  59. KUHLEN M, Willasch AM, Dalle JH, Wachowiak J, et al
    Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.
    Br J Haematol. 2018;180:82-89.
    PubMed     Text format     Abstract available


  60. ROGERS KA, Huang Y, Ruppert AS, Salem G, et al
    A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
    Br J Haematol. 2018;180:259-266.
    PubMed     Text format     Abstract available


  61. JAIN P, Nogueras Gonzalez GM, Kanagal-Shamanna R, Rozovski U, et al
    The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
    Br J Haematol. 2018;180:33-40.
    PubMed     Text format     Abstract available


  62. REA D, Mahon FX
    How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
    Br J Haematol. 2018;180:24-32.
    PubMed     Text format     Abstract available


  63. ARUGA Y, Arakawa A, Ono K, Ogawa C, et al
    Pseudo-Chediak-Higashi granules and Auer rods in mixed phenotype acute leukaemia, T/myeloid, not otherwise specified.
    Br J Haematol. 2018;180:175.
    PubMed     Text format    


  64. WANG J, Morrissette J, Lieberman DB, Timlin C, et al
    Utilization of next generation sequencing identifies potentially actionable mutations in chronic lymphocytic leukaemia.
    Br J Haematol. 2018;180:299-301.
    PubMed     Text format    


  65. BENNETT CL, Berger JR, Sartor O, Carson KR, et al
    Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
    Br J Haematol. 2018;180:301-304.
    PubMed     Text format    


  66. IBERRI DJ, Kwong BY, Stevens LA, Coutre SE, et al
    Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.
    Br J Haematol. 2018;180:164-166.
    PubMed     Text format    


  67. DIAMANTI P, Cox CV, Moppett JP, Blair A, et al
    Dual targeting of Hsp90 in childhood acute lymphoblastic leukaemia.
    Br J Haematol. 2018;180:147-149.
    PubMed     Text format    


    December 2017
  68. WOLACH O, Amitai I, DeAngelo DJ
    Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.
    Br J Haematol. 2017;179:705-723.
    PubMed     Text format     Abstract available


  69. PAVIGLIANITI A, Ruggeri A, Volt F, Sanz G, et al
    Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.
    Br J Haematol. 2017;179:790-801.
    PubMed     Text format     Abstract available


  70. KHARFAN-DABAJA MA, Al Malki MM, Deotare U, Raj RV, et al
    Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
    Br J Haematol. 2017;179:781-789.
    PubMed     Text format     Abstract available


  71. ITTEL A, Gervais C, Galoisy AC, M'Kacher R, et al
    Triradial and quadriradial chromosomes detected in a case of B-cell prolymphocytic leukaemia.
    Br J Haematol. 2017;179:704.
    PubMed     Text format    


  72. RAU RE, Carroll AJ, Heerema NA, Arland L, et al
    Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;179:843-846.
    PubMed     Text format    


    November 2017
  73. KOHNKE T, Wittmann VK, Bucklein VL, Lichtenegger F, et al
    Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.
    Br J Haematol. 2017;179:480-487.
    PubMed     Text format     Abstract available


  74. WU B, Slabicki M, Sellner L, Dietrich S, et al
    MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia.
    Br J Haematol. 2017;179:421-429.
    PubMed     Text format     Abstract available


  75. CHEN Y, Cheng Y, Suo P, Yan C, et al
    Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantati
    Br J Haematol. 2017;179:598-605.
    PubMed     Text format     Abstract available


  76. IGWE IJ, Yang D, Merchant A, Merin N, et al
    The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era - a surveillance, epidemiology, and end results database analysis.
    Br J Haematol. 2017;179:618-626.
    PubMed     Text format     Abstract available


  77. DONADIEU J, Beaupain B, Fenneteau O, Bellanne-Chantelot C, et al
    Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history.
    Br J Haematol. 2017;179:557-574.
    PubMed     Text format     Abstract available


  78. MEDINGER M, Passweg JR
    Acute myeloid leukaemia genomics.
    Br J Haematol. 2017;179:530-542.
    PubMed     Text format     Abstract available


  79. BUSSI C, Iribarren P, Rodriguez CM
    Microtubule-associated protein 1A/1B-light chain 3 (LC3) 'decorates' intracytoplasmic inclusions in a patient with chronic lymphocytic leukaemia.
    Br J Haematol. 2017;179:529.
    PubMed     Text format    


  80. NAITHANI R
    Dasatinib-induced loss of eyebrows.
    Br J Haematol. 2017;179:362.
    PubMed     Text format    


  81. DUTTON D, Roach H, Lowry L
    Splenic rupture following temporary cessation of ibrutinib.
    Br J Haematol. 2017;179:361.
    PubMed     Text format    


  82. MUSGRAVE KM, van Delft FW, Avery PJ, Clack RM, et al
    Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom.
    Br J Haematol. 2017;179:667-669.
    PubMed     Text format    


  83. GORDON MJ, Raess PW, Young K, Spurgeon SEF, et al
    Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
    Br J Haematol. 2017;179:501-503.
    PubMed     Text format    


  84. ABID MB, De Mel S
    Does ponatinib cross the blood-brain barrier?
    Br J Haematol. 2017;179:497-498.
    PubMed     Text format    


    October 2017
  85. HAN LJ, Wang Y, Fan ZP, Huang F, et al
    Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission.
    Br J Haematol. 2017;179:120-130.
    PubMed     Text format     Abstract available


  86. EWINS K, Malone A, Phelan E, Webb D, et al
    Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
    Br J Haematol. 2017;179:294-297.
    PubMed     Text format     Abstract available


  87. STELLRECHT CM, Chen LS, Ayres ML, Dennison JB, et al
    Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy.
    Br J Haematol. 2017;179:266-271.
    PubMed     Text format     Abstract available


  88. EDLINGER L, Berger-Becvar A, Menzl I, Hoermann G, et al
    Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.
    Br J Haematol. 2017;179:229-241.
    PubMed     Text format     Abstract available


  89. HUGHES TP, Munhoz E, Aurelio Salvino M, Ong TC, et al
    Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
    Br J Haematol. 2017;179:219-228.
    PubMed     Text format     Abstract available


  90. MO XD, Lv M, Huang XJ
    Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.
    Br J Haematol. 2017;179:184-197.
    PubMed     Text format     Abstract available


  91. MALONE A, Smith OP
    Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
    Br J Haematol. 2017;179:179-181.
    PubMed     Text format    


  92. YANAGISAWA R, Ogiso Y, Yoshikawa K, Tanaka M, et al
    Myelomonocytic differentiation associated with NPM1-RARA rearrangement.
    Br J Haematol. 2017;179:183.
    PubMed     Text format    


  93. SCHEFFOLD A, Jebaraj BMC, Jaramillo S, Tausch E, et al
    Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.
    Br J Haematol. 2017;179:342-346.
    PubMed     Text format    


    September 2017
  94. ALVAREZ-LARRAN A, Senin A, Fernandez-Rodriguez C, Pereira A, et al
    Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
    Br J Haematol. 2017;178:764-771.
    PubMed     Text format     Abstract available


  95. ZHANG X, Yang L, Liu X, Nie Z, et al
    Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
    Br J Haematol. 2017;178:728-738.
    PubMed     Text format     Abstract available


  96. FENAUX P, Muus P, Kantarjian H, Lyons RM, et al
    Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
    Br J Haematol. 2017;178:906-913.
    PubMed     Text format     Abstract available


  97. GOCKERITZ E, Vondey V, Guastafierro A, Pizevska M, et al
    Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
    Br J Haematol. 2017;178:949-953.
    PubMed     Text format     Abstract available


  98. GHAMLOUCH H, Nguyen-Khac F, Bernard OA
    Chronic lymphocytic leukaemia genomics and the precision medicine era.
    Br J Haematol. 2017;178:852-870.
    PubMed     Text format     Abstract available


  99. KANTOROVA B, Malcikova J, Brazdilova K, Borsky M, et al
    Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients.
    Br J Haematol. 2017;178:979-982.
    PubMed     Text format    


  100. VAN DER HELM LH, Berger G, Diepstra A, Huls G, et al
    Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.
    Br J Haematol. 2017;178:810-812.
    PubMed     Text format    


  101. TRACY I, Tapper W, Parker A, Gardiner A, et al
    Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.
    Br J Haematol. 2017;178:824-826.
    PubMed     Text format    


    August 2017
  102. DUROT E, Tomowiak C, Michallet AS, Dupuis J, et al
    Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14881.
    PubMed     Text format     Abstract available


  103. ZWAAN CM, Kowalczyk J, Schmitt C, Bielorai B, et al
    Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14874.
    PubMed     Text format     Abstract available


  104. SCHETELIG J, de Wreede LC, Andersen NS, Moreno C, et al
    Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
    Br J Haematol. 2017;178:521-533.
    PubMed     Text format     Abstract available


  105. STRATI P, Parikh SA, Chaffee KG, Kay NE, et al
    Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
    Br J Haematol. 2017;178:394-402.
    PubMed     Text format     Abstract available


  106. ZELLER B, Glosli H, Forestier E, Ha SY, et al
    Hyperleucocytosis in paediatric acute myeloid leukaemia - the challenge of white blood cell counts above 200 x 109 /l. The NOPHO experience 1984-2014.
    Br J Haematol. 2017;178:448-456.
    PubMed     Text format     Abstract available


  107. KARLSSON L, Forestier E, Hasle H, Jahnukainen K, et al
    Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.
    Br J Haematol. 2017;178:592-602.
    PubMed     Text format     Abstract available


  108. MESSINA M, Chiaretti S, Fedullo AL, Piciocchi A, et al
    Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts.
    Br J Haematol. 2017;178:583-587.
    PubMed     Text format     Abstract available


  109. EYRE TA, Schuh A
    An update for Richter syndrome - new directions and developments.
    Br J Haematol. 2017;178:508-520.
    PubMed     Text format     Abstract available


  110. SHVIDEL L
    Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
    Br J Haematol. 2017;178:347-348.
    PubMed     Text format    


  111. KWONG JHY, Leung RYY, Wong MLG, Gill H, et al
    Primary myelofibrosis presenting in acute promyelocytic transformation.
    Br J Haematol. 2017;178:349.
    PubMed     Text format    


  112. TAN RMR, Ganau M, Jeelani NUO, Tahir Z, et al
    Central nervous system aspergillosis resembling haemorrhagic brain infarct in a paediatric leukaemia patient.
    Br J Haematol. 2017;178:642-645.
    PubMed     Text format    


    July 2017
  113. CHEN Y, Pourabdollah M, Chang H
    Acute myeloid leukemia with mutated NPM1 demonstrating multilineage dysplasia and marked thrombocytosis.
    Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14741.
    PubMed     Text format    


  114. THEUNISSEN PMJ, van den Branden A, Van Der Sluijs-Gelling A, De Haas V, et al
    Understanding the reconstitution of the B-cell compartment in bone marrow and blood after treatment for B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2017;178:267-278.
    PubMed     Text format     Abstract available


  115. WILLIAMS J, Heppel NH, Britt-Compton B, Grimstead JW, et al
    Telomere length is an independent prognostic marker in MDS but not in de novo AML.
    Br J Haematol. 2017;178:240-249.
    PubMed     Text format     Abstract available


  116. ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
    Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults.
    Br J Haematol. 2017;178:106-111.
    PubMed     Text format     Abstract available


  117. MARTINI V, Gattazzo C, Frezzato F, Trimarco V, et al
    Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
    Br J Haematol. 2017;178:81-93.
    PubMed     Text format     Abstract available


  118. THEUNISSEN PMJ, Sedek L, De Haas V, Szczepanski T, et al
    Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
    Br J Haematol. 2017;178:257-266.
    PubMed     Text format     Abstract available


  119. SOARES M, Saussoy P, Maskens M, Reul H, et al
    Eliminating malignant cells from cryopreserved ovarian tissue is possible in leukaemia patients.
    Br J Haematol. 2017;178:231-239.
    PubMed     Text format     Abstract available


  120. JONES JA, Hillmen P, Coutre S, Tam C, et al
    Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
    Br J Haematol. 2017;178:286-291.
    PubMed     Text format     Abstract available


  121. STRATI P, Parikh SA, Chaffee KG, Achenbach SJ, et al
    CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2017;178:99-105.
    PubMed     Text format     Abstract available


  122. TSUKAMOTO S, Kumazoe M, Huang Y, Lesnick C, et al
    SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cells.
    Br J Haematol. 2017;178:155-158.
    PubMed     Text format    


    June 2017
  123. HO G, Jonas BA, Li Q, Brunson A, et al
    Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.
    Br J Haematol. 2017;177:791-799.
    PubMed     Text format     Abstract available


  124. ONIDA F, de Wreede LC, van Biezen A, Eikema DJ, et al
    Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Br J Haematol. 2017;177:759-765.
    PubMed     Text format     Abstract available


  125. LIU CY, Hsieh FS, Chu PY, Tsai WC, et al
    Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
    Br J Haematol. 2017;177:726-740.
    PubMed     Text format     Abstract available


  126. KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
    The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
    Br J Haematol. 2017;177:1000-1007.
    PubMed     Text format     Abstract available


  127. CORREA DE ARAUJO KOURY L, Ganser A, Berliner N, Rego EM, et al
    Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience.
    Br J Haematol. 2017;177:979-983.
    PubMed     Text format     Abstract available


  128. KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
    Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal.
    Br J Haematol. 2017;177:991-999.
    PubMed     Text format     Abstract available


    May 2017
  129. TAO L, Clarke CA, Rosenberg AS, Advani RH, et al
    Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Br J Haematol. 2017 May 25. doi: 10.1111/bjh.14638.
    PubMed     Text format     Abstract available


  130. EPPERLA N, Pham AQ, Burnette BL, Wiseman GA, et al
    Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
    Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14688.
    PubMed     Text format     Abstract available


  131. SCOTT S, Travis D, Whitby L, Bainbridge J, et al
    Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.
    Br J Haematol. 2017;177:414-422.
    PubMed     Text format     Abstract available


  132. RHEINGOLD SR, Tasian SK, Whitlock JA, Teachey DT, et al
    A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
    Br J Haematol. 2017;177:467-474.
    PubMed     Text format     Abstract available


  133. THOMPSON PA, Stingo F, Keating MJ, Wierda WG, et al
    Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.
    Br J Haematol. 2017;177:567-577.
    PubMed     Text format     Abstract available


  134. THOMPSON PA, Ravandi F
    How I manage patients with hairy cell leukaemia.
    Br J Haematol. 2017;177:543-556.
    PubMed     Text format     Abstract available


  135. NIBLOCK A, McConville DO, Morrison PJ
    Zygodactyly is strongly associated with Acute Myeloid Leukaemia.
    Br J Haematol. 2017;177:659-660.
    PubMed     Text format    


  136. EYRE TA, Fox CP, Shankara P, Went R, et al
    Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
    Br J Haematol. 2017;177:486-491.
    PubMed     Text format    


    April 2017
  137. MARTIN P, Chen Z, Cheson BD, Robinson KS, et al
    Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14667.
    PubMed     Text format     Abstract available


  138. TOKUNAGA M, Yonekura K, Nakamura D, Haraguchi K, et al
    Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14634.
    PubMed     Text format    


  139. BULDINI B, Rizzati F, Masetti R, Fagioli F, et al
    Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
    Br J Haematol. 2017;177:116-126.
    PubMed     Text format     Abstract available


  140. ORLOWSKI RJ, Porter DL, Frey NV
    The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.
    Br J Haematol. 2017;177:13-26.
    PubMed     Text format     Abstract available


  141. AKAHANE K, Li Z, Etchin J, Berezovskaya A, et al
    Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;177:271-282.
    PubMed     Text format     Abstract available


  142. CURTIS DJ
    Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?
    Br J Haematol. 2017;177:169-170.
    PubMed     Text format    


  143. CHAN KL, Blombery P, Jones K, Lade S, et al
    Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.
    Br J Haematol. 2017;177:324-328.
    PubMed     Text format    


  144. FLEMING S, Ong DM, Jackson K, Avery S, et al
    Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia.
    Br J Haematol. 2017;177:328-330.
    PubMed     Text format    


  145. DELGADO J, Bielig T, Bonet L, Carnero-Montoro E, et al
    Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens.
    Br J Haematol. 2017;177:147-150.
    PubMed     Text format    


    March 2017
  146. MINAMI M, Arita T, Iwasaki H, Muta T, et al
    Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib.
    Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14608.
    PubMed     Text format     Abstract available


  147. MARQUET J, Piris-Villaespesa M, Rodriguez E, Lopez S, et al
    Skin lesions and cytological features in HTLV-1 associated adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14600.
    PubMed     Text format    


  148. TASIAN SK, Hunger SP
    Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
    Br J Haematol. 2017;176:867-882.
    PubMed     Text format     Abstract available


  149. CHETTY T, Masingi NI, Laher Z, Pretorius E, et al
    Acute megakaryoblastic leukaemia: light microscopy and scanning electron microscopy of blast cells.
    Br J Haematol. 2017;176:686.
    PubMed     Text format    


  150. GROVE CS, Bolli N, Manes N, Varela I, et al
    Rapid parallel acquisition of somatic mutations after NPM1 in acute myeloid leukaemia evolution.
    Br J Haematol. 2017;176:825-829.
    PubMed     Text format    


  151. QUINQUENEL A, Sicre de Fontbrune F, Durot E, Pannetier M, et al
    Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation.
    Br J Haematol. 2017;176:997-999.
    PubMed     Text format    


  152. TAM CS, Kimber T, Seymour JF
    Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
    Br J Haematol. 2017;176:829-831.
    PubMed     Text format    


    February 2017
  153. SAWAS A, Farber CM, Schreeder MT, Khalil MY, et al
    A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
    Br J Haematol. 2017 Feb 21. doi: 10.1111/bjh.14534.
    PubMed     Text format     Abstract available


  154. SHARMAN JP, Farber CM, Mahadevan D, Schreeder MT, et al
    Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
    Br J Haematol. 2017;176:412-420.
    PubMed     Text format     Abstract available


  155. RINGDEN O, Labopin M, Schmid C, Sadeghi B, et al
    Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
    Br J Haematol. 2017;176:431-439.
    PubMed     Text format     Abstract available


  156. WAN H, Cai J, Chen F, Zhu J, et al
    SOX12: a novel potential target for acute myeloid leukaemia.
    Br J Haematol. 2017;176:421-430.
    PubMed     Text format     Abstract available


  157. BERTAINA A, Vinti L, Strocchio L, Gaspari S, et al
    The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Br J Haematol. 2017;176:629-636.
    PubMed     Text format     Abstract available


  158. VARGHESE AM, Howard DR, Pocock C, Rawstron AC, et al
    Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
    Br J Haematol. 2017;176:573-582.
    PubMed     Text format     Abstract available


  159. CHANG CK, Zhao YS, Xu F, Guo J, et al
    TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
    Br J Haematol. 2017;176:600-608.
    PubMed     Text format     Abstract available


  160. ROBAK T, Hellmann A, Kloczko J, Loscertales J, et al
    Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
    Br J Haematol. 2017;176:618-628.
    PubMed     Text format     Abstract available


  161. LUBBERT M, Ihorst G, Sander PN, Bogatyreva L, et al
    Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Br J Haematol. 2017;176:609-617.
    PubMed     Text format     Abstract available


  162. GAYNON PS
    "The Second Time is Sweeter After All".
    Br J Haematol. 2017;176:511-512.
    PubMed     Text format    


  163. BRANDER DM
    Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?
    Br J Haematol. 2017;176:337-340.
    PubMed     Text format    


  164. GUPTA A, Das A, Naina HV
    Cholecystitis as the initial presentation of acute myeloid leukaemia.
    Br J Haematol. 2017;176:344.
    PubMed     Text format    


  165. COELHO-SILVA JL, Carvalho LE, Oliveira MM, Franca-Neto PL, et al
    Prognostic importance of CD56 expression in intermediate risk acute myeloid leukaemia.
    Br J Haematol. 2017;176:498-501.
    PubMed     Text format    


  166. BAI S, Hu S
    BCR-ABL1-negative acute myeloid leukaemia relapsing as BCR-ABL1-positive disease.
    Br J Haematol. 2017;176:514.
    PubMed     Text format    


    January 2017
  167. WANQUET A, Birsen R, Bonnet C, Boubaya M, et al
    Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
    Br J Haematol. 2017;176:37-49.
    PubMed     Text format     Abstract available


  168. BROWN FC, Cifani P, Drill E, He J, et al
    Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
    Br J Haematol. 2017;176:86-91.
    PubMed     Text format     Abstract available


  169. SEKIYA Y, Xu Y, Muramatsu H, Okuno Y, et al
    Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;176:248-257.
    PubMed     Text format     Abstract available


  170. ZEIDAN AM, Smith BD, Carraway HE, Gojo I, et al
    A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
    Br J Haematol. 2017;176:241-247.
    PubMed     Text format     Abstract available


  171. HASLE H, Kaspers GJ
    Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review.
    Br J Haematol. 2017;176:168-178.
    PubMed     Text format     Abstract available


  172. FRISHMAN-LEVY L, Izraeli S
    Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy.
    Br J Haematol. 2017;176:157-167.
    PubMed     Text format     Abstract available


  173. MAGEE JA
    Comment on: Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
    Br J Haematol. 2017;176:5-6.
    PubMed     Text format    


  174. PAN X, Nariai N, Fukuhara N, Saito S, et al
    Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing.
    Br J Haematol. 2017;176:318-321.
    PubMed     Text format    


    September 2016
  175. BIGENWALD C, Harel S, Chevignon F, Roos-Weil D, et al
    Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
    Br J Haematol. 2016 Sep 23. doi: 10.1111/bjh.14323.
    PubMed     Text format    


  176. BRAS AE, Beishuizen A, Langerak AW, Jongen-Lavrencic M, et al
    CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy.
    Br J Haematol. 2016 Sep 8. doi: 10.1111/bjh.14310.
    PubMed     Text format    


    June 2016
  177. GAYNON PS, Sun W
    Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:950-7.
    PubMed     Text format     Abstract available


  178. WILLIAMS ME, Hong F, Gascoyne RD, Wagner LI, et al
    Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
    Br J Haematol. 2016;173:867-75.
    PubMed     Text format     Abstract available


  179. GIONA F, Moleti ML, De Benedittis D, Santopietro M, et al
    Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience.
    Br J Haematol. 2016;173:749-53.
    PubMed     Text format     Abstract available


  180. ZUNA J, Moericke A, Arens M, Koehler R, et al
    Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:742-8.
    PubMed     Text format     Abstract available


    May 2016
  181. TUCKER DL, Mihailescu L, Riordan R, Rule S, et al
    Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
    Br J Haematol. 2016 May 12. doi: 10.1111/bjh.14118.
    PubMed     Text format    


  182. SOVERINI S, De Benedittis C, Mancini M, Martinelli G, et al
    Present and future of molecular monitoring in chronic myeloid leukaemia.
    Br J Haematol. 2016;173:337-49.
    PubMed     Text format     Abstract available


  183. FERRET Y, Caillault A, Sebda S, Duez M, et al
    Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis.
    Br J Haematol. 2016;173:413-20.
    PubMed     Text format     Abstract available


    March 2016
  184. TAKAHASHI H, Watanabe T, Kinoshita A, Yuza Y, et al
    High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.
    Br J Haematol. 2016 Mar 31. doi: 10.1111/bjh.14068.
    PubMed     Text format     Abstract available


  185. BURKHARDT B, Mueller S, Khanam T, Perkins SL, et al
    Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.
    Br J Haematol. 2016 Mar 15. doi: 10.1111/bjh.14017.
    PubMed     Text format     Abstract available


  186. MILES RR, Shah RK, Frazer JK
    Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2016 Mar 11. doi: 10.1111/bjh.14011.
    PubMed     Text format     Abstract available


    November 2015
  187. GIBSON SE, Leeman-Neill RJ, Jain S, Piao W, et al
    Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene.
    Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13844.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: